Related Experiment Video
Updated: Aug 18, 2026
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model
Simon D Baines1, Jane Freeman, Mark H Wilcox
1Department of Microbiology, University of Leeds and The General Infirmary, Old Medical School, Leeds LS1 3EX, UK.
Objectives:
Clostridium difficile infection (CDI) is a major cause of morbidity in the nosocomial environment. Antimicrobial agents such as the third-generation cephalosporins, lincosamides and aminopenicillins are well known for their propensity to induce CDI, but the definitive reasons why remain to be elucidated. Despite their broad spectrum of activity against both aerobic and anaerobic bacteria, the ureidopenicillins remain a class of antimicrobials infrequently associated with the development of CDI.
Methods:
We used a triple-stage chemostat model that simulates the human gut to study the effects of the ureidopenicillin/beta-lactamase inhibitor combination piperacillin/tazobactam on gut bacterial populations and C. difficile.
Results:
Piperacillin/tazobactam rapidly reduced all enumerated gut bacterial populations (including bacteroides, bifidobacteria and lactobacilli) below the limits of detection by the end of the piperacillin/tazobactam instillation period. Despite such widespread disruption of gut bacterial populations, C. difficile populations remained principally as spores, with no sustained proliferation or high-level cytotoxin production observed.
Conclusions:
Factors other than reduced colonization resistance must be responsible for determining whether CDI develops following antimicrobial administration. We believe the gut model is a promising approach for the study of C. difficile pathogenesis reflecting in vivo events likely to occur in CDI.
Insights
Piperacillin/tazobactam significantly disrupted gut bacteria but did not cause Clostridium difficile infection (CDI) proliferation. This suggests factors beyond colonization resistance influence CDI development after antibiotic use.
Area of Science:
- Microbiology
- Gastroenterology
- Infectious Diseases
Background:
- Clostridium difficile infection (CDI) is a significant nosocomial pathogen.
- Certain antibiotics (cephalosporins, lincosamides, aminopenicillins) are known to induce CDI.
- Ureidopenicillins are infrequently associated with CDI, despite broad-spectrum activity.
Purpose of the Study:
- To investigate the impact of piperacillin/tazobactam on gut microbiota and C. difficile dynamics.
- To elucidate the reasons behind the low association of ureidopenicillins with CDI.
Main Methods:
- Utilized a triple-stage chemostat model simulating the human gut.
- Assessed the effects of piperacillin/tazobactam on indigenous gut bacteria and C. difficile.
Main Results:
- Piperacillin/tazobactam drastically reduced gut bacterial populations, including Bacteroides, Bifidobacteria, and Lactobacilli.
- C. difficile remained primarily in spore form, with no significant proliferation or cytotoxin production observed during treatment.
Conclusions:
- Reduced colonization resistance alone may not explain CDI development post-antibiotic exposure.
- The chemostat gut model shows promise for studying C. difficile pathogenesis in vivo.
